RxDoctor Payments Data

Amy Larson

Physician Assistant · Prince Frederick, MDNPI 1417285784

Payments from drug & device makers

$5,405in general payments, 2019–2025

Across 351 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • AbbVie$956
  • Collegium Pharmaceutical, Inc.$898
  • Boston Scientific$625
  • Pfizer$224
  • Scilex Pharmaceuticals Inc.$217
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$5,405100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,405 in reported general payments places this provider in the 90th percentile of 2,567 physician assistant providers in Maryland.

See all physician assistant providers in Maryland

Medicare billing

Part B allowed, 2024
$311,202
Medicare patients
442
Services billed
9,723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate101$60,062
OxycontinOxycodone Hcl100$58,610
Oxycodone Hcl1,299$25,654
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen639$24,823
BelbucaBuprenorphine Hcl32$23,414
Nucynta ErTapentadol Hcl13$9,826
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen335$8,043
Lidocaine83$6,639
Morphine Sulfate ErMorphine Sulfate261$6,346
Gabapentin383$5,314
Fentanyl41$4,480
Buprenorphine26$4,291
Diclofenac Sodium76$4,130
Tramadol Hcl ErTramadol Hcl24$4,053
Pregabalin201$3,849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er$898$93,302146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,567 physician assistant providers in Maryland.

Other physician assistant in Prince Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →